TABLE 5.
%dd-cfDNA by DSA/PRA status in N = 280 biopsies
| Biopsies group by %dd-cfDNA | DSA-negative (N=220) | DSA-positive or PRAHRa (N = 60) | ||||||
|---|---|---|---|---|---|---|---|---|
| PRA-negative(N = 93) | PRA-positiveDSA-negative(N = 127) | All DSA-negative(N = 220) | I(N = 9) | II(N = 29) | I/II(N = 6) | PRAHR(N =16) | All DSA-positive or PRAHR(N = 60) | |
| %dd-cfDNA ≥1%(N = 104) | 22 | 45 | 67 | 5 | 21 | 3 | 8 | 37 |
| %dd-cfDNA 0.10–0.99(N = 138) | 57 | 60 | 117 | 3 | 8 | 3 | 7 | 21 |
| %dd-cfDNA <0.1%(N = 38) | 14 | 22 | 36 | 1 | 0 | 0 | 1 | 2 |
Bolding indicates all DSA-negative or all DSA-positive/PRAHR.
a
Biopsies from PRA-positive patients with missing/unavailable donor phenotyping to assign DSA status were called PRAHR in this study.
dd-cfDNA, donor-derived cell-free DNA; DSA, donor-specific antibody; PRA, panel-reactive antibody; PRAHR, panel-reactive antibody–high risk.